JBI-589

Last updated

JBI-589
JBI-589 structure.png
Identifiers
  • [(3R)-3-aminopiperidin-1-yl]-[2-[1-[(4-fluorophenyl)methyl]indol-2-yl]-3-methylimidazo[1,2-a]pyridin-7-yl]methanone
CAS Number
PubChem CID
ChemSpider
ECHA InfoCard 100.383.687 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C29H28FN5O
Molar mass 481.575 g·mol−1
3D model (JSmol)
  • CC1=C(N=C2N1C=CC(=C2)C(=O)N3CCC[C@H](C3)N)C4=CC5=CC=CC=C5N4CC6=CC=C(C=C6)F
  • InChI=1S/C29H28FN5O/c1-19-28(32-27-16-22(12-14-34(19)27)29(36)33-13-4-6-24(31)18-33)26-15-21-5-2-3-7-25(21)35(26)17-20-8-10-23(30)11-9-20/h2-3,5,7-12,14-16,24H,4,6,13,17-18,31H2,1H3/t24-/m1/s1
  • Key:DUVCPNSLXBKGOK-XMMPIXPASA-N

JBI-589 is an experimental drug which acts as an orally active, selective inhibitor of the enzyme peptidylarginine deiminase 4 (PAD4). It has antiinflammatory effects and has been researched for potential use in the treatment of arthritis and some forms of cancer. [1] [2] [3] [4]

See also

References

  1. Deng H, Lin C, Garcia-Gerique L, Fu S, Cruz Z, Bonner EE, et al. (October 2022). "A Novel Selective Inhibitor JBI-589 Targets PAD4-Mediated Neutrophil Migration to Suppress Tumor Progression". Cancer Research. 82 (19): 3561–3572. doi:10.1158/0008-5472.CAN-21-4045. PMC   9532374 . PMID   36069973.
  2. Gajendran C, Fukui S, Sadhu NM, Zainuddin M, Rajagopal S, Gosu R, et al. (February 2023). "Alleviation of arthritis through prevention of neutrophil extracellular traps by an orally available inhibitor of protein arginine deiminase 4". Scientific Reports. 13 (1) 3189. Bibcode:2023NatSR..13.3189G. doi:10.1038/s41598-023-30246-2. PMC   9950073 . PMID   36823444.
  3. Heger LA, Schommer N, Fukui S, Van Bruggen S, Sheehy CE, Chu L, et al. (October 2023). "Inhibition of protein arginine deiminase 4 prevents inflammation-mediated heart failure in arthritis". Life Science Alliance. 6 (10) e202302055. doi:10.26508/lsa.202302055. PMC   10374941 . PMID   37500179.
  4. Mansouri P, Mansouri P, Behmard E, Najafipour S, Kouhpayeh SA, Farjadfar A (October 2024). "Peptidylarginine deiminase (PAD): A promising target for chronic diseases treatment". International Journal of Biological Macromolecules. 278 (Pt 3) 134576. doi:10.1016/j.ijbiomac.2024.134576. PMID   39127273.